# Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies

> **NCT00666081** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK690693

## Key facts

- **NCT ID:** NCT00666081
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Cancelled before enrollment
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666081, "Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00666081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*